Zydus Cadila Acquires Six Brands from Merck India
Ahmedabad-based drug maker Zydus Cadila has acquired six brands from the Indian unit of US pharmaceutical giant Merck for an undisclosed amount.
Zydus in a release late on Wednesday said it has acquired Deca-Durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten range from Merck Sharp and Dohme (MSD).
The acquired portfolio clocked in sales of . 84 crore in 2015, it said. The brands fall in ` men’s and women’s health, wound management and cardiovascular therapy segments.
ET had reported in August that MSD was looking to sell a range of products as part of a rationalisation drive that would see sharper focus on select core brands.
Its deal with Zydus includes transfer of dis tribution and commercialisation rights as well as assignment of trademarks of all the six brands to Zydus Healthcare Ltd in India.
Organon (India), one of the legal subsidia ries through which MSD operates in India, has also The brands fall transferred the distribuin men’s tion and commercialisa& women’s tion rights for Deca-Durahealth, wound bolin and Durabolin for Nemgmt and pal to Zydus.cardio therapy The acquisition is expecsegments ted to strengthen Zydus’ portfolio in key therapeutic segments. “We look at this as a great opportunity to strengthen our core offerings to create value and growth,“ Zydus Healthcare chairman Sharvil Patel said.
The drug maker’s share prices closed 0.20% . 350.45 on the BSE.higher at ` ries through which MSD operates in India, has also transferred the distribution and commercialisation rights for Deca-Durabolin and Durabolin for Nepal to Zydus.
The acquisition is expected to strengthen Zydus’ portfolio in key therapeutic segments. “We look at this as a great opportunity to strengthen our core offerings to create value and growth,“ Zydus Healthcare chairman Sharvil Patel said.